IRIDEX (IRIX) Receiving Somewhat Favorable Media Coverage, Analysis Finds
News stories about IRIDEX (NASDAQ:IRIX) have been trending somewhat positive on Thursday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. IRIDEX earned a news impact score of 0.17 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.4756318631727 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
IRIDEX (NASDAQ:IRIX) opened at $8.70 on Thursday. IRIDEX has a 52 week low of $7.43 and a 52 week high of $16.37.
Several research analysts recently issued reports on the company. Zacks Investment Research cut IRIDEX from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Roth Capital reissued a “buy” rating and issued a $13.00 price objective on shares of IRIDEX in a research note on Friday, November 3rd.
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
Receive News & Stock Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related stocks with our FREE daily email newsletter.